Metastatic breast cancer trials recruiting in New York

All Metastatic breast cancer trials nationally

Cities in New York

Recruiting trials in New York

• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
  NCT06678269 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Rochester
• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
  NCT06099769 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
  NCT06110793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
  NCT06246968 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
  NCT04683679 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · New York: Commack, Harrison, New York, Uniondale
• A Study of Surgery and Radiotherapy in People With Breast Cancer
  NCT07053085 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
  NCT05534438 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Shirley
• Comprehensive Outcomes for After Cancer Health
  NCT05349227 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Definitive Radiation for High-Risk Spine Metastases
  NCT06165419 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Stony Brook
• Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
  NCT06405828 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · New York: New York
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
  NCT05696626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
  NCT03808337 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
  NCT03449238 · Phase: Phase 1, Phase 2 · Ages: 19 Years to 90 Years · Sex: Female · New York: New York
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
  NCT06072612 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Babylon, Manhattan, New Hyde Park, New York
• Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
  NCT05846789 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo